Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant

Next Previous
X
Search
Trial Profile

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venglustat (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms MOVES-PD
  • Sponsors Sanofi; Sanofi Genzyme

    • Most Recent Events

    • 01 Aug 2023 Results assessing assess the safety, efficacy, and target engagement of venglustat in people with early-stage Parkinson's disease carrying pathogenic GBA1 variants published in the Lancet Neurology
    • 22 Sep 2021 Primary endpoint (Part 2: Change in Movement Disorder Society Unified Parkinsons Disease Rating Scale Part II and III score, performed during the OFF state) has not been met, according to Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
    • 22 Sep 2021 Results of part 2 presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top